Revisiting traditional risk factors for rejection and graft loss after kidney transplantation

American Journal of Transplantation

Volumn 11, Issue 10, 2011, Pages 2132-2143

  Dunn, T B ^a   Noreen, H ^b   Gillingham, K ^a   Maurer, D ^b   Ozturk, O G ^c   Pruett, T L ^a   Bray, R A ^c   Gebel, H M ^c   Matas, A J ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Antibody mediated rejection; retransplant; risk; sensitization

Indexed keywords

ANTIBODY; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DONOR SPECIFIC ANTIBODY; MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CELL MEDIATED REJECTION; CREATININE CLEARANCE; DEATH CENSORED GRAFT SURVIVAL; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETRANSPLANTATION; RISK FACTOR;

EID: 80053307061     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03640.x     Document Type: Article

References (34)

1. Bryan CF, Baier KA, Nelson PW, et al,. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 1998; 66: 1827-1832. (Pubitemid 29035015)
2. Mulder A, Kardol MJ, Kamp J, et al,. Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals. Clin Exp Immunol 2001; 124: 9-15. (Pubitemid 32476929)
3. Kerman RH, Orosz CG, Lorber MI,. Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci 1997; 313: 275-278. (Pubitemid 27198238)
4. Gebel HM, Bray RA,. Sensitization and sensitivity: Defining the unsensitized patient. Transplantation 2000; 69: 1370-1374. (Pubitemid 30238726)
5. Zeevi A, Girnita A, Duquesnoy R,. HLA antibody analysis: Sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res 2006; 36: 255-264. (Pubitemid 46398602)
6. Leffell MS, Zachary AA,. Antiallograft antibodies: Relevance, detection, and monitoring. Curr Opin Organ Transplant 2010; 15: 2-7.
7. Racusen LC, Solez K, Colvin RB, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723. (Pubitemid 29082898)
8. Racusen LC, Colvin RB, Solez K, et al,. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714. (Pubitemid 36745243)
9. Solez K, Colvin RB, Racusen LC, et al,. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
10. Salvatierra O Jr,., Perkins HA, Amend W Jr,., et al. The influence of presensitization on graft survival rate. Surgery 1977; 81: 146-151. (Pubitemid 8033876)
11. Koka P, Cecka JM,. Sensitization and crossmatching in renal transplantation. Clin Transpl 1989; 12: 379-390.
12. Stratta RJ, Oh CS, Sollinger HW, Pirsch JD, Kalayoglu M, Belzer FO,. Kidney retransplantation in the cyclosporine era. Transplantation 1988; 45: 40-45. (Pubitemid 18084606)
13. Almond PS, Matas AJ, Gillingham K, et al,. Risk factors for second renal allografts immunosuppressed with cyclosporine. Transplantation 1991; 52: 253-258.
14. Flechner SM, Lorber MI, Kerman RH, Van Buren CT, Wideman C, Kahan BD,. Does cyclosporine influence the results of cadaver retransplantation? Hum Immunol 1985; 14: 305-313. (Pubitemid 16213558)
15. House AA, Chang PC, Luke PP, et al,. Re-exposure to mismatched HLA class I is a significant risk factor for graft loss: Multivariable analysis of 259 kidney retransplants. Transplantation 2007; 84: 722-728. (Pubitemid 47480657)
16. Gruber SA, Brown KL, El-Amm JM, et al,. Equivalent outcomes with primary and retransplantation in African-American deceased-donor renal allograft recipients. Surgery 2009; 146: 646-652; Discussion 52-53.
17. Sanfilippo F, Vaughn WK, LeFor WM, Spees EK,. Multivariate analysis of risk factors in cadaver donor kidney transplantation. Transplantation 1986; 42: 28-34. (Pubitemid 16058471)
18. Deng CT, El-Awar N, Ozawa M, Cai J, Lachmann N, Terasaki PI,. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008; 86: 452-459.
19. Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M,. Positive remote crossmatch: Impact on short-term and long-term outcome in cadaver renal transplantation. Transplantation 2003; 75: 501-505. (Pubitemid 36241147)
20. Khwaja K, Asolati M, Harmon J, et al,. Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4: 980-987. (Pubitemid 38745597)
21. Cho YW, Cecka JM,. Crossmatch tests-an analysis of UNOS data from 1991-2000. Clin Transpl 2001; 15: 237-246.
22. Halloran PF, Schlaut J, Solez K, Srinivasa NS,. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550-555.
23. Cosio FG, Lager DJ, Lorenz EC, Amer H, Gloor JM, Stegall MD,. Significance and implications of capillaritis during acute rejection of kidney allografts. Transplantation 2010; 89: 1088-1094.
24. Poggio ED, Augustine JJ, Clemente M, et al,. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83: 847-852. (Pubitemid 46682724)
25. Pearl JP, Parris J, Hale DA, et al,. Immunocompetent T cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005; 5: 465-474. (Pubitemid 40313337)
26. Lynch RJ, Platt JL,. Accommodation in renal transplantation: Unanswered questions. Curr Opin Organ Transplant 2010; 15: 481-485.
27. Gurkan S, Luan Y, Dhillon N, et al,. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10: 2132-2141.
28. Haas M, Rahman MH, Racusen LC, et al,. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840. (Pubitemid 44024954)
29. Pollinger HS, Stegall MD, Gloor JM, et al,. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857-863. (Pubitemid 46481187)
30. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al,. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324-331.
31. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S,. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-1688.
32. Loupy A, Suberbielle-Boissel C, Hill GS, et al,. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
33. Gebel HM, Bray RA, Nickerson P,. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500. (Pubitemid 37541506)
34. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F,. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.